Page 41 - டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

March 5, 2021 healthcare Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome − Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study − Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations − Takeda plans to initiate Phase 3 studies in children and adults with Dravet syndrome and Lennox-Gastaut syndrome in calendar year Q2 2021

United statesSarah sheikhJeremy levinTakeda shonanExchange commissionTakeda pharmaceutical company limitedOvid therapeutics incTakeda pharmaceutical companyPharmaceutical company limitedOvid therapeuticsAndy plumpChief executive officerNeuroscience therapeutic area unitNew treatment optionsDravet syndromeConference call